Ken Griffin Lantern Pharma Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 42,800 shares of LTRN stock, worth $182,755. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,800
Previous 19,900
115.08%
Holding current value
$182,755
Previous $175,000
13.71%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding LTRN
# of Institutions
41Shares Held
1.26MCall Options Held
42.8KPut Options Held
5.6K-
Vanguard Group Inc Valley Forge, PA364KShares$1.55 Million0.0% of portfolio
-
New Edge Advisors, LLC New Orleans, LA157KShares$670,9190.01% of portfolio
-
Geode Capital Management, LLC Boston, MA86.3KShares$368,7010.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny81.8KShares$349,2850.0% of portfolio
-
Cm Management, LLC80KShares$341,5990.35% of portfolio
About Lantern Pharma Inc.
- Ticker LTRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,830,900
- Market Cap $46.2M
- Description
- Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...